Constellation Software: The Capital-Allocation Machine at Full Price
A ROIC spread of almost 13 percentage points — and still no margin of safety. Why CSU is great and the price, frankly, is exhausting.
The consensus on Constellation Software has been the same for years: the best capital-allocation model in the Western public markets, a compounder you buy and never touch again. That consensus took a crack in 2026. The stock fell roughly 40% from its high, because the market is asking for the first time, seriously, whether AI-assisted software development erodes the moats of the thousand niche providers that CSU has bought up over three decades.
The interesting question is therefore not "is CSU a good company" — it is, and the numbers below prove it unambiguously. The question is whether the fallen price now offers a margin of safety. My answer after working through fiscal year 2025: no, not yet.
The Foundation: a Business That Needs Almost No Capital
CSU earns three-quarters of its money from recurring maintenance and recurring revenue — in FY2025 that was 8,700 of 11,623 million USD in revenue. The business generates high, predictable cash flow while tying up almost no operating capital, because customers pay in advance: the deferred-revenue balance of USD 2,891 million practically finances the ongoing business. This is exactly what makes the ROIC calculation so peculiar — and so revealing.
| Metric (FY2025, USD million) | Value | Derivation / source |
|---|---|---|
| EBIT (after amortization & impairment) | 1,852 | Revenue 11,623 − expense 9,728 − impairment 43 |
| Tax rate (normalized) | 27 % | between 19% Q1'26 effective and the cash rate; reported 37.6% distorted by non-deductible reval. |
| NOPAT | 1,352 | 1,852 × (1 − 0.27) |
| Invested capital incl. | 6,965 | interest-bearing debt 5,787 + equity 4,267 − cash 3,089 |
| Acquisition intangibles (book value) | 8,368 | goodwill 1,782 + technology 2,606 + customer 3,980 |
| Invested capital excl. | −1,403 | 6,965 − 8,368 → negative |
| WACC | 6.5 % | Ke 6.8% (CAPM, β 0.66) · Kd 5.5% · D/V 10.5% |
The ROIC Finding: Three Lenses, One Conclusion
| Lens | ROIC | Spread vs. WACC | What it measures |
|---|---|---|---|
| Incl. intangibles (book value) | 19.4 % | +12.9 pp | Return on the capital currently tied up |
| Leonard logic (cash NOPAT / gross IC) | 16.2 % | +9.6 pp | Return on all capital ever deployed in M&A (13,703 million) |
| Excl. intangibles | n/a | ∞ | Core business is financed with negative capital |
The third finding is the real bombshell. Strip out the acquired intangibles and invested capital turns negative: the operating core business needs less capital than CSU carries in equity and debt. Economically, that means operating capital efficiency is effectively infinite. Every dollar of value creation arises not in operations, but at the point where surplus cash is allocated into new acquisitions.
Where the Growth Comes From — and Where It Doesn't
This logic is cemented when you break down the reinvestment. Organically, the reinvestment rate is negative (around −10% of NOPAT): the business actually frees up capital through its negative working capital. The whole game runs through acquisitions — and there CSU reinvests roughly 80% of its free cash flow.
| Year | FCF (USD million) | Net income (USD million) | FCF / NI | M&A / FCF |
|---|---|---|---|---|
| 2017 | 508 | 222 | 229 % | 50 % |
| 2019 | 733 | 333 | 220 % | 69 % |
| 2021 | 1,271 | 310 | 410 % | 93 % |
| 2022 | 1,256 | 512 | 245 % | 125 % |
| 2023 | 1,737 | 565 | 307 % | 98 % |
| 2024 | 2,129 | 731 | 291 % | 71 % |
| 2025 | 2,664 | 512 | 520 % | 50 % |
| Avg. 2017–25 | — | — | 302 % | 75 % |
The driver of this gap is an item most analyses overlook: the amortization of capitalized contract costs ("deferred charges"). It came to USD 689 million in 2025 and thus exceeded even the amortization of acquisition intangibles (505 million). Both are non-cash charges that depress book earnings without ever costing cash. Add the two together and you explain most of the USD 2.2 billion by which free cash flow exceeded net income in 2025.
The FCF series also demonstrates the robustness of the machine. Over eight years, free cash flow grew at roughly 23% per year, with only a single — and marginal — down year (2022, −1.2%). Such consistency across a full cycle including the rate-hiking turn is rare and the strongest empirical argument against the AI bear: so far, nothing has slowed the cash generation.
The Financing Question: Under Its Own Power, or on Credit?
A common bear objection at serial acquirers is that growth is debt-financed. The cash-flow calculation refutes that for CSU — with a revealing nuance. Until 2020, CSU financed its acquisitions entirely from free cash flow after dividends; net debt usage was minimal. With the large deals of 2021–2023 (Allscripts, Optimal Blue), meaningful leverage came into play for the first time — in 2022, a financing gap of roughly USD 400 million flowed into debt.
What matters is what happened next: in 2024 and 2025, free cash flow grew faster than M&A volume, so CSU again generated a clear surplus (in 2025 roughly USD 1.2 billion above the M&A requirement). The interest burden from the senior notes issued in 2024 is comfortably bearable at about 8% of free cash flow. CSU has thus demonstrated that it uses leverage when needed but can also reduce it under its own power — a proof of discipline, not a warning sign.
Valuation: Great Is Priced In
Because CSU reports levered free cash flow after interest (FCFA2S = USD 1,683 million in FY2025), I discount this directly with the cost of equity — no renewed debt deduction. Three scenarios, each with its own discount rate and terminal growth:
Bear
1,525 CAD
Discount 11.0% · term-g 2.5%
AI erodes moats, organic growth below 4%, more expensive M&A environment.
−49 %
Base
2,693 CAD
Discount 9.5% · term-g 3.5%
M&A machine runs, growth normalizes to 10–14%.
−9 %
Bull
4,648 CAD
Discount 8.5% · term-g 4.5%
Retirement wave of software founders delivers more targets, AI lowers costs across the portfolio.
+57 %
Probability-weighted (30 / 50 / 20), this yields a fair value of 2,734 CAD — roughly 8% below the current price of 2,969 CAD. The terminal-value share is 78–85%, which is unavoidable at a compounder but should be read as a warning sign: almost all of the value lies beyond the forecast horizon and thus hangs on a long-term growth assumption that is precisely what AI is now calling into question.
Bear Case Made Honest
Bull
- Structurally the best capital allocation, +13 pp ROIC spread, consistent for decades.
- Negative working capital — the business finances its own growth.
- FCF exceeds earnings by a factor of 3 — the true multiple is ~18x, not 60x.
- FCF CAGR 23% over 8 years, only one marginal down year — robust through the cycle.
- Retirement wave of software founders enlarges the pool of acquisition targets.
- Decentralized model is built against key-person risk.
Bear
- AI lowers entry barriers in exactly the niches that make up CSU's moat.
- Organic growth only 4% — no growth without M&A.
- If the M&A environment gets more expensive, the value-creation equation breaks.
- Mark Leonard is not standing for re-election to the board — the end of an era.
- 78–85% of the DCF value lies in the terminal value.
Conclusion
CSU is outstanding in quality — the ROIC finding and the nine-year cash-flow series leave no doubt about that. Important for context: the optically off-putting P/E of 60 misleads. On a free-cash-flow basis, which on average exceeds net income threefold, CSU trades closer to 18–19x. But that, too, is fair value, not a discount. My weighted fair value lies roughly 8% below the price; even after the 40% crash, the stock offers no margin of safety, but at best fair value against a real, new risk (AI). Position sizing: For existing holders, no reason to sell — the machine works, and cash flow keeps growing double-digit. For new entrants, I would proceed in stages and open a first tranche only below ~2,400 CAD (approaching the bear/base midpoint), with add-ons only if the AI bear proves overstated and FCF generation stays stable. Patience is the position here.
To be verified against the original filing: (1) the normalized tax rate of 27% — I interpolated between the effective Q1-2026 rate of 19% and the cash tax rate; (2) the EBIT delineation, whether impairment and FX are to be treated as operating or one-off; (3) the treatment of the IRGA liability as a financial liability in invested capital; (4) the beta approach of 0.85 instead of the reported 0.66 for the discount rate.